

Shigellosis - Pipeline Insight, 2021

<https://marketpublishers.com/r/S314CE9F4291EN.html>

Date: February 2021

Pages: 60

Price: US\$ 1,500.00 (Single User License)

ID: S314CE9F4291EN

Abstracts

This report can be delivered to the clients within 48-72 Hours

DelveInsight's, "Shigellosis - Pipeline Insight, 2021," report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Shigellosis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Shigellosis Understanding

Shigellosis: Overview

Shigellosis is a bacterial infection caused by a group of bacteria called Shigella. It affects the digestive system. Shigella is very contagious and spread through contaminated water and food or via contact with contaminated feces. The bacteria release toxins that irritate the intestines. The primary symptom of shigellosis is diarrhea. Shigella are usually found in the feces of infected people. The bacteria are spread when someone comes into contact with the stool of an infected person, or with something that has been contaminated with the stool or the bacteria. Contaminated food and water are also a common cause of shigellosis. The main goal of treatment is preventing dehydration for most cases of shigellosis. Treatment usually includes antibiotics to eliminate the bacteria from the digestive tract.

"Shigellosis- Pipeline Insight, 2021" report by DelveInsight outlays comprehensive

insights of present scenario and growth prospects across the indication. A detailed picture of the Shigellosis pipeline landscape is provided which includes the disease overview and Shigellosis treatment guidelines. The assessment part of the report embraces, in depth Shigellosis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Shigellosis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Shigellosis R&D. The therapies under development are focused on novel approaches to treat/improve Shigellosis.

Shigellosis Emerging Drugs Chapters

This segment of the Shigellosis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Shigellosis Emerging Drugs

Shigella 4v: GlycoVaxyn

It is a biconjugate (Tetravalent) vaccine. Currently, in phase II of clinical trials for the treatment of shigella infection.

SF2a-TT15: Institut Pasteur

A synthetic carbohydrate-based Shigella flexneri 2a vaccine candidate.

Further product details are provided in the report.....

Shigellosis: Therapeutic Assessment

This segment of the report provides insights about the different Shigellosis drugs

segregated based on following parameters that define the scope of the report, such as:

Major Players in Shigellosis

There are approx. 5+ key companies which are developing the therapies for Shigellosis. The companies which have their Shigellosis drug candidates in the mid to advanced stage, i.e. Phase II include, GlycoVaxyn and others.

Phases

DelveInsight's report covers around 5+ products under different phases of clinical development like

Late-stage products (Phase III)

Mid-stage products (Phase II and Phase II/II)

Early-stage products (Phase I/II and Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Shigellosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Subcutaneous

Intravenous

Oral

Parenteral

Intramuscular

Molecule Type

Products have been categorized under various Molecule types such as

Small molecules

Peptides

Polymer

Gene Therapy

Monoclonal antibodies

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Shigellosis: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Shigellosis therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Shigellosis drugs.

Shigellosis Report Insights

Shigellosis Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

Shigellosis Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

How many companies are developing Shigellosis drugs?

How many Shigellosis drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Shigellosis?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Shigellosis therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Shigellosis and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

GlycoVaxyn

Institut Pasteur

GlaxoSmithKline

Key Products

SF2a-TT15

Shigella 4v

1790GAHB vaccine

Contents

- Introduction
- Executive Summary
- Shigellosis: Overview
 - Causes
 - Mechanism of Action
 - Signs and Symptoms
 - Diagnosis
 - Disease Management
- Pipeline Therapeutics
 - Comparative Analysis
- Therapeutic Assessment
 - Assessment by Product Type
 - Assessment by Stage and Product Type
 - Assessment by Route of Administration
 - Assessment by Stage and Route of Administration
 - Assessment by Molecule Type
 - Assessment by Stage and Molecule Type
- Shigellosis – DelveInsight’s Analytical Perspective
- In-depth Commercial Assessment
 - Shigellosis companies’ collaborations, Licensing, Acquisition -Deal Value Trends
- Shigellosis Collaboration Deals
 - Company-Company Collaborations (Licensing / Partnering) Analysis
 - Company-University Collaborations (Licensing / Partnering) Analysis
- Late Stage Products (Phase III)
 - Comparative Analysis
- Drug name: Company name
 - Product Description
 - Research and Development
 - Product Development Activities
- Drug profiles in the detailed report.....
- Mid Stage Products (Phase II)
 - Comparative Analysis
- Shigella 4v: GlycoVaxyn
 - Product Description
 - Research and Development
 - Product Development Activities
- Drug profiles in the detailed report.....

Pre-clinical and Discovery Stage Products
 Comparative Analysis
Drug name: Company name
 Product Description
 Research and Development
 Product Development Activities
Drug profiles in the detailed report.....
Inactive Products
 Comparative Analysis
Shigellosis Key Companies
Shigellosis Key Products
Shigellosis- Unmet Needs
Shigellosis- Market Drivers and Barriers
Shigellosis- Future Perspectives and Conclusion
Shigellosis Analyst Views
Shigellosis Key Companies
Appendix

List Of Tables

LIST OF TABLES

- Table 1 Total Products for Shigellosis
- Table 2 Late Stage Products
- Table 3 Mid Stage Products
- Table 4 Early Stage Products
- Table 5 Pre-clinical & Discovery Stage Products
- Table 6 Assessment by Product Type
- Table 7 Assessment by Stage and Product Type
- Table 8 Assessment by Route of Administration
- Table 9 Assessment by Stage and Route of Administration
- Table 10 Assessment by Molecule Type
- Table 11 Assessment by Stage and Molecule Type
- Table 12 Inactive Products

List Of Figures

LIST OF FIGURES

- Figure 1 Total Products for Shigellosis
- Figure 2 Late Stage Products
- Figure 3 Mid Stage Products
- Figure 4 Early Stage Products
- Figure 5 Preclinical and Discovery Stage Products
- Figure 6 Assessment by Product Type
- Figure 7 Assessment by Stage and Product Type
- Figure 8 Assessment by Route of Administration
- Figure 9 Assessment by Stage and Route of Administration
- Figure 10 Assessment by Molecule Type
- Figure 11 Assessment by Stage and Molecule Type
- Figure 12 Inactive Products

I would like to order

Product name: Shigellosis - Pipeline Insight, 2021

Product link: <https://marketpublishers.com/r/S314CE9F4291EN.html>

Price: US\$ 1,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/S314CE9F4291EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970